(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Hematology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets's offering.
Fully revised and updated, the report provides details of 192 hematology deals from 2016 to 2025.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the world's leading biopharma companies.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of hematology dealmaking and business activities. Chapter 1 offers an introduction to the report, and chapter 2 analyzes hematology dealmaking trends. Chapter 3 outlines financial deal terms for signed hematology deals, categorized by headline value, upfront payment, milestone payment, and royalty rates. Chapter 4 reviews the top 25 most active biopharma companies in hematology dealmaking, providing contract access links. Chapter 5 delivers a detailed review of hematology deals since 2016 with available contract documents. Lastly, Chapter 6 offers a directory of hematology deals sorted by therapeutic target.
The report also includes numerous tables and figures that illustrate the trends and activities in hematology deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Hematology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse hematology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in hematology dealmaking
2.1. Introduction
2.2. Hematology partnering over the years
2.3. Hematology partnering by deal type
2.4. Hematology partnering by industry sector
2.5. Hematology partnering by stage of development
2.6. Hematology partnering by technology type
2.7. Hematology partnering by therapeutic indication
Chapter 3 - Financial deal terms for hematology partnering
3.1. Introduction
3.2. Disclosed financials terms for hematology partnering
3.3. Hematology partnering headline values
3.4. Hematology deal upfront payments
3.5. Hematology deal milestone payments
3.6. Hematology royalty rates
Chapter 4 - Leading hematology deals and dealmakers
4.1. Introduction
4.2. Most active in hematology partnering
4.3. List of most active dealmakers in hematology
4.4. Top hematology deals by value
Chapter 5 - Hematology contract document directory
5.1. Introduction
5.2. Hematology partnering deals where contract document available
Chapter 6 - Hematology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by hematology therapeutic target
Companies Featured

• 2seventy bio
• Abbvie
• ABVC BioPharma
• Acceleron Pharma
• Acrotech Biopharma
• Adaptive Biotechnologies
• AgeX Therapeutics
• Agilent Technologies
• AkaRx
• Akebia Therapeutics
• Albert Einstein College of Medicine
• Alfasigma
• Amag Pharmaceuticals
• American Society of Hematology
• Anthos Therapeutics
• Apellis Pharmaceuticals
• Arbor Biotechnologies
• Aruvant Sciences
• Association for the Advancement of Blood & Biotherapies
• AstraZeneca
• Baxalta
• Baxter International
• Beam Therapeutics
• Becton Dickinson
• Bill and Melinda Gates Foundation
• BillionToOne
• Bioceros
• BioMatrix Specialty Pharmacy
• Blau Pharma
• Blood Centers of America
• Bluebird Bio
• Brooklyn ImmunoTherapeutics
• Cadila Pharmaceuticals
• Celgene
• Centogene
• Children's Hospital of Philadelphia
• City of Hope
• Codexis
• CRISPR Therapeutics
• Danaher
• Duke University
• Editas Medicine
• Eisai
• Emendo Biotherapeutics
• Enable Injections
• Enzyre
• Esperion Therapeutics
• Evive Biotechnology
• Fibrogen
• Foresee Pharmaceuticals

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112025004107003653ID1110368225